Nutrients review finds thin direct evidence for tirzepatide after sleeve gastrectomy

The wire

1. 01A critical review across PubMed, Scopus, Web of Science, Cochrane and ClinicalTrials.gov concludes tirzepatide may produce clinically meaningful weight reduction after sleeve gastrectomy, but direct evidence is limited.
2. 02Clinicians managing weight recurrence after bariatric surgery are already using dual GIP/GLP-1 agonists off the back of indirect data.
3. 03Uncertainties flagged include long-term efficacy, durability after discontinuation, fat-free mass preservation and nutritional safety; this is a narrative review, not new trial data.

From the source

Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications

Nutrients · 2026 Sep 23 · Ciołkosz K, Polak-Szczybyło E et al.